Search > Human Metapneumovirus Infection
144 Participants NeededMy employer runs this trial

AZD0543 for Human Metapneumovirus Infection

Recruiting at 1 trial location
AC
Overseen ByAstraZeneca Clinical Study Information Center
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: AstraZeneca

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to assess the safety and PK of AZD0543 compared to placebo in healthy adults 18 to 55 years of age. AZD0543 or placebo will be administered as single IM or IV dose. The study duration will be approximately 12 months for each participant following administration of IMP.

Are You a Good Fit for This Trial?

This trial is for healthy adults aged 18 to 55 who do not have any significant health problems. Participants should not have conditions that could affect their safety or the study results.

Inclusion Criteria

I am between 18 and 55 years old.
Body weight ≥ 45 kg and ≤ 110 kg and BMI within the range ≥ 18.0 kg/m2 to ≤ 30 kg/m2

Exclusion Criteria

Hypersensitivity to IMP/components
I have a serious bleeding disorder.
Screening abnormalities: clinically significant ECG, positive drug panel, Hgb/platelets/WBC outside of reference; all SCr/AST/ALT > 1.5X ULN
See 9 more

What Are the Treatments Tested in This Trial?

Interventions

  • AZD0543

Trial Overview

The study is testing a new drug called AZD0543, given as a single injection into the muscle or vein, compared to a placebo (inactive substance). The main goal is to see how safe it is and how the body processes it over about one year.

How Is the Trial Designed?

6

Treatment groups

Experimental Treatment

Placebo Group

Group I: Cohort 3: High Dose AZD0543Experimental Treatment1 Intervention
Group II: Cohort 2: Medium Dose AZD0543Experimental Treatment1 Intervention
Group III: Cohort 1: Low Dose AZD0543Experimental Treatment1 Intervention
Group IV: Cohort 2: PlaceboPlacebo Group1 Intervention
Group V: Cohort 1: PlaceboPlacebo Group1 Intervention
Group VI: Cohort 3: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials
4,491
Recruited
290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.